AnaptysBio, Inc. (ANAB)

AnaptysBio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	22.96	17.16	10.29	63.18	75	8
Revenue Growth (YoY)	114.78%	66.78%	-83.72%	-15.77%	837.50%	60.00%
Gross Profit	22.96	17.16	10.29	63.18	75	8
Selling, General & Admin	43.47	41.95	36.64	21.49	18.85	16.09
Research & Development	134.37	132.28	88.8	98.5	80.03	99.34
Other Operating Expenses	7.34	7.34	0	0	0	0
Operating Expenses	185.17	181.57	125.44	119.99	98.88	115.43
Operating Income	-162.21	-164.41	-115.15	-56.81	-23.88	-107.43
Interest Expense / Income	0	0	0	0	0	1.04
Other Expense / Income	1.09	-0.79	13.55	0.98	-3.95	-10.99
Pretax Income	-163.3	-163.62	-128.7	-57.8	-19.93	-97.49
Income Tax	-0	-0	0.02	0	0	-0.15
Net Income	-163.3	-163.62	-128.72	-57.8	-19.93	-97.34
Shares Outstanding (Basic)	27	27	28	27	27	27
Shares Outstanding (Diluted)	27	27	28	27	27	27
Shares Change	-4.12%	-4.41%	2.68%	0.47%	0.90%	9.67%
EPS (Basic)	-6.14	-6.08	-4.57	-2.11	-0.73	-3.60
EPS (Diluted)	-6.14	-6.08	-4.57	-2.11	-0.73	-3.60
Free Cash Flow	-134.14	-121.61	-73.95	-47.27	-14.73	-70.32
Free Cash Flow Per Share	-5.00	-4.52	-2.63	-1.72	-0.54	-2.60
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-706.43%	-958.27%	-1119.41%	-89.93%	-31.84%	-1342.90%
Profit Margin	-711.17%	-953.66%	-1251.33%	-91.49%	-26.57%	-1216.70%
Free Cash Flow Margin	-584.20%	-708.79%	-718.88%	-74.83%	-19.63%	-879.03%
EBITDA	-160.92	-161.25	-126.37	-55.71	-18.31	-95.04
EBITDA Margin	-700.79%	-939.83%	-1228.40%	-88.18%	-24.42%	-1188.00%
Depreciation & Amortization	2.39	2.38	2.34	2.09	1.62	1.41
EBIT	-163.3	-163.62	-128.7	-57.8	-19.93	-96.45
EBIT Margin	-711.19%	-953.68%	-1251.09%	-91.49%	-26.57%	-1205.59%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).